Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients

Expert Review of Hematology

Volumn 4, Issue 3, 2011, Pages 285-299

  Hiwase, Devendra K ^a,b   Yeung, David T ^a,b   White, Deborah L ^a,b,c  

^a Rundle Mall   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

CML; dasatinib; imatinib; nilotinib; TKI

Indexed keywords

CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB; PEGINTERFERON;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; ORGANIC CATION TRANSPORT PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 79959250885     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.19     Document Type: Review

References (106)

1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497 (1960)
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290-293 (1973)
3. Druker BJ, Guilhot F, O Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006)
4. Deininger M, O Brien SG, Guilhot F et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Presented at: 51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5-8 December 2009.
5. Kantarjian H, Talpaz M, O Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8), 2873-2878 (2004)
6. Kantarjian HM, Talpaz M, O Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2), 473-475 (2003)
7. Cortes J, Giles F, O Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-a. Blood 102(1), 83-86 (2003)
8. Kantarjian HM, Larson RA, Guilhot F et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3), 551-560 (2009).
9. Cortes JE, Baccarani M, Guilhot F et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28(3), 424-430 (2010)
10. + IFN in CML: the randomized German CML-study IV. Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4-7 December 2010.
11. Castagnetti F, Palandri F, Amabile M et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a Phase 2 trial of the GIMEMA CML Working Party. Blood 113(15), 3428-3434 (2009)
12. Baccarani M, Rosti G, Castagnetti F et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphiα positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113(19), 4497-4504 (2009)
13. Preudhomme C, Guilhot J, Nicolini FE et al. Imatinib plus peginterferon α2a in chronic myeloid leukemia. N. Engl. J. Med. 363(26), 2511-2521 (2010)
14. Hughes TP, Branford S, White DL et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112(10), 3965-3973 (2008)
15. Palandri F, Castagnetti F, Iacobucci I et al. The combination of interferon-a with imatinib in early chronic phase chronic myeloid leukemia patients induces a significant improvement of the molecular responses in the first two years of treatment: results from three studies from the GIMEMA CML working party. Presented at: 51st Annual meeting of American Society of Hematology. New Orleans, LA, USA, 5-8 December 2009.
16. Cortes J, Borthakur G, O Brien S et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)Blood 114(22), 338 (2009)
17. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260-2270 (2010)
18. Muller MC, Cortes JE, Kim DW et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR- ABL mutations. Blood 114(24), 4944-4953 (2009)
19. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129-141 (2005)
20. + chronic myeloid leukemia (CML): results of a Phase 2 GIMEMA CML WP clinical trial. Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4-7 December 2010.
21. + chronic myeloid leukemia. Blood 114(24), 4933-4938 (2009)
22. Cortes JE, Jones D, O Brien S et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol. 28(3), 392-397 (2010)
23. Hughes T, Hochhaus A, Saglio G et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4-7 December 2010.
24. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251-2259 (2010)
25. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 63(4), 789-799 (1984)
26. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon a. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J. Natl Cancer Inst. 90(11), 850-858 (1998)
27. White D, Saunders V, Lyons AB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106(7), 2520-2526 (2005)
28. White D, Saunders V, Grigg A et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J. Clin. Oncol. 25(28), 4445-4451 (2007)
29. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12), 3739-3745 (2004)
30. White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2), 697-704 (2006)
31. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110(12), 4064-4072 (2007)
32. White DL, Dang P, Engler J et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J. Clin. Oncol. 28(16), 2761-2767 (2010)
33. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 106(3), 1133-1134 (2005)
34. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporterhOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther. 83(2), 258-264 (2008)
35. Zhang WW, Cortes JE, Yao H et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol. 27(22), 3642-3649 (2009)
36. Hiwase DK, Saunders V, Hewett D et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res. 14(12), 3881-3888 (2008)
37. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112(8), 3348-3354 (2008)
38. Hegedus C, Ozvegy-Laczka C, Apati A et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol. 158(4), 1153-1164 (2009)
39. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27(35), 6041-6051 (2009)
40. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR- ABL. Leukemia 20(4), 664-670 (2006)
41. Branford S, Rudzki Z, Parkinson I et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104(9), 2926-2932 (2004)
42. Marin D, Milojkovic D, Olavarria E et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112(12), 4437-4444 (2008)
43. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6), 1809-1820 (2006)
44. de Lavallade H, Apperley JF, Khorashad JS et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26(20), 3358-3363 (2008)
45. Alvarado Y, Kantarjian H, O Brien S et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16), 3709-3718 (2009)
46. Hughes TP, Hochhaus A, Branford S et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP)Presented at: 50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, 6-9 December 2008.
47. Hughes TP, Hochhaus A, Branford S et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood 116(19), 3758-3765 (2010)
48. Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8), 3496-3499 (2007)
49. Larson RA, Druker BJ, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8), 4022-4028 (2008)
50. Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22), 5401-5411 (2009)
51. Marin D, Bazeos A, Mahon FX et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28(14), 2381-2388 (2010)
52. Jabbour E, Kantarjian H, Jones D et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10), 1767-1773 (2006)
53. Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1), 276-283 (2003)
54. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11), 2190-2196 (2002)
55. Soverini S, Martinelli G, Amabile M et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem, 50(7), 1205-1213 (2004)
56. Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 18(4), 864-871 (2004)
57. Ernst T, Erben P, Muller MC et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93(2), 186-192 (2008)
58. Branford S, Goh H-G, Izzo B et al. A review of mutation analysis in the tops trial of standard dose versus high dose IM in CML suggests that refinements to the ELN recommendations for mutation screening may be appropriate. ASH Annual Meeting Abstracts 116(21), 889 (2010)
59. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 114(13), 2598-2605 (2009)
60. Tsaur G, Ivanova A, Popov A et al. Evaluation of BCR-ABL/ABL ratio increase that corresponds to BCR-ABL mutation in chronic myeloid leukemia patients treated by imatinib. ASH Annual Meeting Abstracts 116(21), 3422 (2010).
61. Wang L, Knight K, Lucas C, Clark RE. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 91(2), 235-239 (2006)
62. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am. Soc. Hematol. Educ. Program 2005(1), 183-187 (2005)
63. Hochhaus A, Druker B, Sawyers C et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-a treatment. Blood 111(3), 1039-1043 (2008)
64. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 99(10), 3530-3539 (2002)
65. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99(6), 1928-1937 (2002)
66. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001)
67. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475 (2002)
68. Cowan-Jacob SW, Guez V, Fendrich G et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 4(3), 285-299 (2004)
69. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2), 117-125 (2002)
70. Hughes T, Saglio G, Branford S et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 27(25), 4204-4210 (2009)
71. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8(11), 1018-1029 (2007)
72. Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109(10), 4143-4150 (2007)
73. Soverini S, Colarossi S, Gnani A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphiα positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12(24), 7374-7379 (2006)
74. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109(8), 3207-3213 (2007)
75. + ALL)Blood 110(2), 727-734 (2007)
76. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114(27), 5426-5435 (2009)
77. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiαchromosome-positive leukaemia to STI571: a prospective study. Lancet 359(9305), 487-491 (2002)
78. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99(5), 1860-1862 (2002)
79. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2), 690-698 (2003)
80. Hiwase DK, White DL, Powell JA et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24(4), 771-778 (2010)
81. + progenitors via JAK- 2/STAT-5 pathway activation. Blood 109(5), 2147-2155 (2007)
82. + leukemic cells to the abl inhibitor STI571. J. Natl Cancer Inst. 92(20), 1641-1650 (2000)
83. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6), 2368-2373 (2003)
84. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood 109(12), 5143-5150 (2007)
85. Kantarjian H, Pasquini R, Levy V et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized Phase 2 study (START-R)Cancer 115(18), 4136-4147 (2009)
86. Mauro M, Baccarani M, Cervantes F et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)J. Clin. Oncol. 26(20 Suppl.), 7009 (2008)
87. Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6), 1200-1206 (2008)
88. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6), 2303-2309 (2007)
89. Jabbour E, Kantarjian HM, Jones D et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13), 4839-4842 (2008)
90. Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphiαpositive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92(3), 401-404 (2007).
91. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354(24), 2542-2551 (2006)
92. Cortes J, Jabbour E, Kantarjian H et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12), 4005-4011 (2007)
93. + neoplastic cells. Cancer Res. 66(23), 11314-11322 (2006)
94. Bruemmendorf T, Cervantes F, Kim D, Chandy M, Fischer T, Hochhaus A. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Presented at: 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
95. Milojkovic D, Nicholson E, Apperley JF et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95(2), 224-231 (2010)
96. Jabbour E, Kantarjian H, O Brien S et al. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6), 1822-1827 (2010)
97. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10), 3540-3546 (2007)
98. Jabbour E, Kantarjian H, Jones D et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1), 53-55 (2008)
99. Nicolini FE, Morisset S, Hochhaus A et al. The presence of the BCR-ABL T315I mutation in chronic phase chronic myelogenous leukemia resistant to tyrosine kinase inhibitors profoundly compromises overall survival and progression free survival. Preliminary results of a matched pair analysis. Blood 116(21), 3410 (2010)
100. Cortes J, Talpaz M, Bixby D et al. A Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 116(21), 210 (2010)
101. Cortes-Franco J, Dombret H, Schafhausen P et al. Danusertib hydrochloride (PHα739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Presented at: 51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5-8 December 2009.
102. Cortes J, Roboz GJ, Kantarjian HM et al. A Phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Presented at: 50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, 6-9 December 2008.
103. Cortes JE, Wetzler M, Lipton J et al. Subcutaneous omacetaxine (OM) treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure. Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4-7 December 2010.
104. Branford S, Kim D-W, Soverini S et al. Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP)Presented at: 51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5-8 December 2009.
105. Tam CS, Kantarjian H, Garci-Manero G et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3), 516-518 (2008)
106. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349(15), 1423-1432 (2003).